1. What Is the Next Generation Sequencing Market?
The Next Generation Sequencing Market covers the massively parallel DNA and RNA sequencing instruments, sequencing reagent consumables, and bioinformatics analysis software. These enable the simultaneous sequencing of billions of DNA fragments to produce the genome, exome, transcriptome, and epigenome data. The data support the oncology precision medicine, rare disease diagnosis, infectious disease genomic epidemiology, liquid biopsy cancer monitoring, and agricultural genomics applications. NGS technology platforms include the short-read sequencing by synthesis for the high-accuracy high-throughput applications and the HiFi long-read SMRT sequencing for the structural variant and full-length isoform characterisation. The platforms also include the real-time nanopore sequencing for the portable sequencing and ultralong read applications that each distinct biochemistry enables. The short-read sequencing-by-synthesis platforms dominate the NGS instrument and consumable market across clinical and research workflows at different throughput scales. The long-read, portable, and cost-sensitive segments have competitive alternative platforms. Oncology comprehensive genomic profiling from tumour tissue and liquid biopsy supports the actionable mutation detection. The rare disease whole genome sequencing, the COVID-19 and mpox viral genomic epidemiology surveillance, and the metagenomics infectious disease testing use culture-independent sequencing. These represent the established clinical NGS applications across oncology, rare disease, and infectious disease medicine.
2. Next Generation Sequencing Market Size & Forecast
3. Emerging Technologies
- Liquid biopsy circulating tumour DNA sequencing from plasma samples uses ultra-deep sequencing at 10,000x coverage. The coverage detects the rare mutant allele fractions of 0.1 percent or below that circulating tumour DNA represents in the plasma of cancer patients. The sequencing provides the non-invasive tumour monitoring that follows treatment response and detects resistance mutations without repeated tumour biopsy. Guardant360 CDx and Foundation Medicine FoundationOne Liquid CDx serve as the FDA-approved clinical ctDNA tests.
- Oxford Nanopore portable sequencing uses the MinION device running on a standard laptop in field settings. The device has demonstrated the pathogen surveillance capability for Ebola, SARS-CoV-2, and yellow fever genomics in resource-limited settings without laboratory infrastructure. The real-time genomic epidemiology supports the rapid outbreak response when central laboratory transport would delay results by weeks.
- Multi-cancer early detection from plasma cfDNA methylation patterns uses machine learning models trained to identify cancer-specific methylation signatures. Grail Galleri has demonstrated it as the first commercially available multi-cancer blood test. The test screens for over 50 cancer types from a single plasma sample in asymptomatic adults.
- PacBio HiFi long-read sequencing provides greater than 99.9 percent read accuracy at 15 to 25 kilobase read lengths. The sequencing enables the complete assembly of repeat-rich genomic regions, structural variant characterisation, and full-length isoform quantification. The short-read Illumina sequencing cannot resolve these due to the read length limitation. The limitation prevents spanning of the repeat sequences and complex structural variants that long reads traverse.
Such innovations are driving change across adjacent industries too. Discover more in our Digital Pcr Market.
4. Key Market Opportunity
The primary commercial opportunity in the Next Generation Sequencing market is clinical NGS adoption expansion across oncology, rare disease, and infectious disease, where NGS-based diagnosis reduces diagnostic odyssey and guides therapy. Illumina and Foundation Medicine (Roche) capture this clinical adoption opportunity. Another growth driver comes from long-read clinical application development. As clinical NGS adoption expands and long-read clinical applications advance, the addressable opportunity is evolving from research-dominated NGS use toward broad clinical diagnostic NGS deployment.
5. Top Companies in the Next Generation Sequencing Market
The following organisations hold leading positions in the Next Generation Sequencing Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Illumina
- Thermo Fisher Scientific
- Pacific Biosciences
- Oxford Nanopore Technologies
- BGI Genomics
- Qiagen
- Roche
- Agilent Technologies
- PerkinElmer
- BioMerieux
- 10x Genomics
- Element Biosciences
- Singular Genomics
- Ultima Genomics
6. Market Segmentation
The Next Generation Sequencing Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Application | OncologyRare DiseaseInfectious DiseaseReproductiveResearch |
| By Technology | Short-Read IlluminaLong-Read Nanopore/PacBioLinked Read |
| By Setting | Clinical LabHospitalResearchDTC |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Next Generation Sequencing Market trajectory over the forecast period:
Liquid Biopsy Ultra-Deep ctDNA Sequencing at 10,000x Coverage Detecting 0.1 Percent Mutant Allele Fractions Is Enabling Non-Invasive Tumour Monitoring and Resistance Mutation Detection Without Repeated Tissue Biopsy.Illumina's NovaSeq X Plus achieving USD 200 whole-genome sequencing and the iSeq 100 desktop sequencer providing accessible sequencing for smaller laboratories represent the sequencing platform range that Illumina provides across the research and clinical market. The clinical genomics applications of NGS including hereditary cancer gene panels, pharmacogenomics testing, and tumour mutation profiling for oncology precision medicine have driven the development of FDA-cleared NGS-based IVD assays from Foundation Medicine, Guardant Health, and Illumina's TruSight Oncology series. The global genomics data generation has reached tens of millions of human genomes sequenced annually as the cost reduction trajectory from USD 100 million for the first human genome to below USD 200 today has enabled population-scale genomics programmes including UK Biobank, All of Us, and China Precision Medicine Initiative.
Oxford Nanopore MinION Portable Sequencing on a Laptop in Field Settings Has Demonstrated Real-Time Pathogen Genomic Surveillance for Ebola and COVID-19 in Resource-Limited Settings Without Laboratory Infrastructure.Oxford Nanopore's PromethION 24 and MinION portable sequencer and Pacific Biosciences' Revio HiFi sequencer provide the long-read sequencing platforms that structural genomics, plant genomics, and clinical applications including tandem repeat disorder characterisation require for the read lengths of 10,000 to over 100,000 base pairs. The complete human genome sequencing achievement of the Telomere-to-Telomere consortium using Pacific Biosciences and Oxford Nanopore to sequence the 8 percent of the human genome not resolved by short-read assembly demonstrated the capability that long-read sequencing brings to completing the full human reference genome. The Oxford Nanopore adaptive sampling feature that selects which DNA molecules to sequence in real time based on early basecall results enables targeted sequencing of specific genomic regions without PCR amplification or probe-based enrichment, simplifying clinical structural variant detection for repeat expansion disorder diagnosis.
Multi-Cancer Early Detection Blood Tests Using cfDNA Methylation ML Models Have Made Pan-Cancer Screening From a Single Plasma Draw Commercially Available for the First Time With Grail Galleri Detecting Over 50 Cancer Types.The single-cell atlas projects including the Human Cell Atlas cataloguing transcriptional profiles of all human cell types and the Human Tumour Atlas characterising the cellular ecosystem of human cancers provide the reference frameworks that single-cell NGS data interpretation uses to assign cell type identities to observed transcriptional profiles. The spatial transcriptomics extension using 10x Genomics' Visium, Nanostring CosMx, and Vizgen MERFISH platforms provides the spatial gene expression maps that reveal tissue organisation, cellular interaction, and tumour-immune interface that dissociated single-cell sequencing cannot address.
For related market intelligence, see the Genetic Testing Market.
8. Segmental Analysis
By application, the oncology and somatic variant calling segment dominated the Next Generation Sequencing Market in 2025, as Foundation Medicine and Tempus anchored comprehensive genomic profiling for biomarker-guided cancer therapy selection, generating the dominant share of clinical NGS revenue.
By technology, the long-read and single-molecule sequencing segment is projected to register the highest growth rate through 2034, as Pacific Biosciences Revio and Oxford Nanopore PromethION scale long-read throughput to enable phased variant calling, structural-variant detection, and methylation profiling that short-read Illumina platforms cannot resolve.
9. Regional Analysis
Regional demand patterns across the Next Generation Sequencing Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Next Generation Sequencing Market in 2025, accounting for approximately 43% of global revenue, due to US premium pricing for clinical NGS and the concentration of Illumina, Foundation Medicine, Guardant Health, and other leading NGS companies. Moreover, clinical oncology NGS adoption is most advanced in the US. In addition, long-read sequencing clinical development is centred in North America. Regional dominance is attributed to this combination of pricing environment and clinical NGS leadership.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Next Generation Sequencing Market through 2034, driven by the large genomics research market in China and India and expanding clinical NGS adoption through healthcare system investment. The region is also witnessing BGI Genomics and other local NGS platform growth. Moreover, population genomics initiatives sustain demand. The combination of these demand drivers and market scale positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Next Generation Sequencing Market was valued at USD 12.48 Bn in 2025 and is projected to reach USD 43.22 Bn by 2034, growing at a CAGR of 14.8% over the 2026–2034 forecast period.
The Next Generation Sequencing Market is projected to grow at a CAGR of 14.8% from 2026 to 2034.
North America dominated the Next Generation Sequencing Market in 2025, accounting for approximately 43% of global revenue, due to US premium pricing for clinical NGS and the concentration of Illumina, Foundation Medicine, Guardant Health, and other leading NGS companies.
The leading companies in the Next Generation Sequencing Market include Illumina, Thermo Fisher Scientific, Pacific Biosciences, Oxford Nanopore Technologies, BGI Genomics, Qiagen, Roche, Agilent Technologies, PerkinElmer, BioMerieux, 10x Genomics, Element Biosciences, Singular Genomics, Ultima Genomics.
Liquid biopsy ultra-deep ctdna sequencing at 10,000x coverage detecting 0.1 percent mutant allele fractions is enabling non-invasive tumour monitoring and resistance mutation detection without repeated tissue biopsy.
By application, the oncology and somatic variant calling segment dominated the Next Generation Sequencing Market in 2025, as Foundation Medicine and Tempus anchored comprehensive genomic profiling for biomarker-guided cancer therapy selection, generating the dominant share of clinical NGS revenue.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.